Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | Phase 2 | withdrawn | Apr 25, 2023 | Uwe Platzbecker | Trial was stopped prematurely due to safety reasons | Safety / toxicity |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic… | Phase 1 / Phase 2 | suspended | Dec 23, 2021 | Cyclacel Pharmaceuticals, Inc. | Slow enrollment and financial limitations | Enrollment / accrual |
| NCT00277056 | Dysregulated Tyrosine Kinase Signaling in Leukemia | — | terminated | Jan 13, 2006 | University of New Mexico | This is not a clinical trial and was entered in the system in error. | Other (stated, no rule matched) |
| NCT01186328 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute… | Phase 1 | terminated | Aug 23, 2010 | Therapeutic Advances in Childhood Leukemia Consortium | Enzon Pharmaceuticals decided to end its development of EZN-3042. | Other (stated, no rule matched) |
| NCT03110354 | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | Phase 1 | terminated | Apr 12, 2017 | Daiichi Sankyo | This study was terminated due to slow accrual. | Enrollment / accrual |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid…(VOYAGE) | Phase 1 / Phase 2 | terminated | Jun 2, 2014 | MacroGenics | Business decision | Sponsor / business decision |
| NCT00630565 | Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia | Phase 2 / Phase 3 | terminated | Mar 7, 2008 | Masonic Cancer Center, University of Minnesota | Slow Accrual | Enrollment / accrual |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Phase 1 / Phase 2 | terminated | Sep 17, 2019 | University Health Network, Toronto | Insufficient Funding | Funding |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Phase 1 | suspended | Aug 9, 2021 | Syros Pharmaceuticals | Prioritization | Other (stated, no rule matched) |
| NCT01898793 | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or… | Phase 1 / Phase 2 | terminated | Jul 12, 2013 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT04785547 | ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | Phase 2 | terminated | Mar 8, 2021 | Prof. Christina Peters | Terminated by Amgen Limited | Other (stated, no rule matched) |
| NCT02580981 | Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses | N/A | terminated | Oct 20, 2015 | New Mexico Cancer Research Alliance | Staffing | Other (stated, no rule matched) |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Dec 12, 2019 | University of Washington | Terminated due to unfavorable risk-benefit ratio of investigational regimen. | Other (stated, no rule matched) |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Oct 4, 2021 | Intellia Therapeutics | Pivoting to an allogeneic version of this program currently in preclinical development. | Other (stated, no rule matched) |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid… | Phase 2 | withdrawn | Dec 26, 2023 | Yale University | Lack of funding. | Funding |
| NCT04803123 | Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r… | Early Phase 1 | terminated | Mar 17, 2021 | Dorothy Sipkins, MD, PhD | Sponsor halted clinical development of study drug | Other (stated, no rule matched) |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI)… | Phase 1 / Phase 2 | withdrawn | Jan 21, 2022 | Naoyuki G. Saito, M.D., Ph.D. | insufficient staff and updates in standard practice have made it difficult to recruit participants | Enrollment / accrual |
| NCT04209725 | A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD… | Phase 2 | terminated | Dec 24, 2019 | SCRI Development Innovations, LLC | Closed due to slow enrollment | Enrollment / accrual |
| NCT04361058 | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With… | Phase 1 | withdrawn | Apr 24, 2020 | SCRI Development Innovations, LLC | The single site that was deemed appropriate for this study was unable to enroll patients. Closed… | Enrollment / accrual |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT05259813 | Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL | Phase 1 | withdrawn | Mar 2, 2022 | Shanghai Ming Ju Biotechnology Co., Ltd. | Due to the COVID-19 pandemic，no subjects enrolled | COVID-19 / pandemic |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid… | Phase 1 | terminated | Apr 5, 2019 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic… | Phase 1 | terminated | Jul 27, 2021 | Vincerx Pharma, Inc. | Slow enrollment | Enrollment / accrual |
| NCT02520011 | Alvocidib Biomarker-driven Phase 2 AML Study | Phase 2 | terminated | Aug 11, 2015 | Sumitomo Pharma America, Inc. | Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the… | Enrollment / accrual |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously… | Phase 1 / Phase 2 | terminated | Jun 28, 2018 | Sumitomo Pharma America, Inc. | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible to… | Other (stated, no rule matched) |
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With… | Phase 2 | terminated | May 31, 2019 | Sumitomo Pharma America, Inc. | Business decision to terminate the development of alvocidib program on 17 November 2020. Patients… | Sponsor / business decision |
| NCT05943314 | Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of… | N/A | withdrawn | Jul 13, 2023 | Guangzhou Bio-gene Technology Co., Ltd | The clinical trial was terminated due to a change in sponsor strategy. | Sponsor / business decision |
| NCT02763384 | BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/… | Phase 2 | terminated | May 5, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Jul 17, 2019 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Phase 1 | terminated | Jan 29, 2020 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic…(REVEAL) | — | suspended | Sep 6, 2018 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in… | Phase 1 / Phase 2 | suspended | Jul 24, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Pause for changes in development strategies | Sponsor / business decision |
| NCT01891981 | Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute… | Phase 1 | terminated | Jul 3, 2013 | M.D. Anderson Cancer Center | Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter | Other (stated, no rule matched) |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors… | Phase 1 | terminated | Oct 1, 2018 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Despite demonstrated safety and tolerability the trial was terminated early due to program… | Safety / toxicity |
| NCT04840784 | First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML | Phase 1 | terminated | Apr 12, 2021 | Shengke Pharmaceuticals Pty Ltd | The reasons for early termination is due to slow recruitment | Enrollment / accrual |
| NCT02096042 | Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | terminated | Mar 26, 2014 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT02957032 | A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein… | Phase 1 | terminated | Nov 7, 2016 | Philogen S.p.A. | New agents for the same indication impacted on patients' recruitment | Enrollment / accrual |
| NCT05961696 | A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic… | Phase 1 | withdrawn | Jul 27, 2023 | M.D. Anderson Cancer Center | 0 accrual | Enrollment / accrual |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or… | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | Bellicum Pharmaceuticals | company decision | Sponsor / business decision |
| NCT04166929 | Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS(Bigeminy) | Phase 2 | terminated | Nov 18, 2019 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | low recruitment | Enrollment / accrual |
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With…(BISECT) | Phase 1 | withdrawn | Jul 13, 2022 | Racura Oncology Ltd | commercial reason | Other (stated, no rule matched) |
| NCT02065869 | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | Phase 1 / Phase 2 | terminated | Feb 19, 2014 | Bellicum Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT03699475 | Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide…(THRIVE) | Phase 2 / Phase 3 | terminated | Oct 9, 2018 | Bellicum Pharmaceuticals | Funding, portfolio re-prioritization | Funding |
| NCT03733249 | Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | Phase 1 / Phase 2 | terminated | Nov 7, 2018 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT03884972 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or… | Phase 1 | withdrawn | Mar 21, 2019 | M.D. Anderson Cancer Center | Request by sponsor due to no enrollment of participants on study | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 12, 2024source: clinicaltrials